Gunderson Dettmer Clients Invest in $215M Series B Financing of Arbor Biotechnologies
Gunderson Dettmer represented clients Illumina Ventures, Section 32, and Tao Capital Partners as investors in the $215 million Series B financing of Arbor Biotechnologies, a developer of transformative therapeutic products. The Massachusetts-based company plans to use its new funding to advance its next-generation precision editing therapeutics.
In the announcement of the transaction, CEO of Arbor Biotechnologies Dr. Devyn Smith said, “By leveraging our proprietary discovery engine — which applies machine learning and AI to mine our protein database containing billions of proteins — we have successfully built the most extensive toolbox of wholly-owned CRISPR genomic editors in the industry. This breadth of tools and IP enables us, and our partners, to approach numerous diseases with gene editing solutions that can be tailored to edit or rewrite the genetic errors that result in disease pathology. This provides us with the ability to target the root cause of genetic diseases.”
The Gunderson deal teams were led by Kirt Shuldberg, Maggie White, and Ryan Gunderson and included Will Fogarty.